India Mulls Panel To Decide Ban Of Fixed-Dose Combos Banned Elsewhere
This article was originally published in PharmAsia News
India regulators reportedly plan to set up a panel of experts to eliminate from the nation's list several approved fixed-dose combination drugs with questionable efficacy still prescribed by physicians.
You may also be interested in...
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance hopes to build a potentially best-in-class presence in a competitive landscape.
An expert panel at the virtual HLTH conference discussed the role of robotics in improving health and wellness in the health continuum. See what Darla Hutton, vice president of US marketing and customer hospital analytics at Intuitive Surgical, said about the future of robotics.
With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years.